676 results on '"Kaech, Susan M."'
Search Results
2. ARID1A suppresses R-loop-mediated STING-type I interferon pathway activation of anti-tumor immunity
3. A bedside to bench study of anti-PD-1, anti-CD40, and anti-CSF1R indicates that more is not necessarily better
4. Parallels Between the Antiviral State and the Irradiated State.
5. CD8+ T cells in the cancer-immunity cycle
6. Immigration in science
7. Canonical BAF complex activity shapes the enhancer landscape that licenses CD8+ T cell effector and memory fates
8. Immunoediting instructs tumor metabolic reprogramming to support immune evasion
9. CTLA-4 blockade induces a microglia-Th1 cell partnership that stimulates microglia phagocytosis and anti-tumor function in glioblastoma
10. Figure S4 from EGFR-Driven Lung Adenocarcinomas Co-opt Alveolar Macrophage Metabolism and Function to Support EGFR Signaling and Growth
11. Data from EGFR-Driven Lung Adenocarcinomas Co-opt Alveolar Macrophage Metabolism and Function to Support EGFR Signaling and Growth
12. Eicosanoids in the Pancreatic Tumor Microenvironment—A Multicellular, Multifaceted Progression
13. Table S1 from EGFR-Driven Lung Adenocarcinomas Co-opt Alveolar Macrophage Metabolism and Function to Support EGFR Signaling and Growth
14. EGFR-Driven Lung Adenocarcinomas Co-opt Alveolar Macrophage Metabolism and Function to Support EGFR Signaling and Growth
15. How metabolism bridles cytotoxic CD8+ T cells through epigenetic modifications
16. Supplementary Table S2 from Combinatorial Immunotherapy with Agonistic CD40 Activates Dendritic Cells to Express IL12 and Overcomes PD-1 Resistance
17. Data from Combinatorial Immunotherapy with Agonistic CD40 Activates Dendritic Cells to Express IL12 and Overcomes PD-1 Resistance
18. Supplementary Figures from Combinatorial Immunotherapy with Agonistic CD40 Activates Dendritic Cells to Express IL12 and Overcomes PD-1 Resistance
19. Mitochondrial DNA stress signalling protects the nuclear genome
20. Manipulating mitochondrial electron flow enhances tumor immunogenicity
21. Memory T Cells in the Immunoprevention of Cancer: A Switch from Therapeutic to Prophylactic Approaches
22. Combinatorial Immunotherapy with Agonistic CD40 Activates Dendritic Cells to Express IL12 and Overcomes PD-1 Resistance
23. A statistical analysis of memory CD8 T cell differentiation: An application of a hierarchical state space model to a short time course microarray experiment
24. A Statistical Analysis of Memory CD8 T Cell Differentiation: An Application of a Hierarchical State Space Model to a Short Time Course Microarray Experiment
25. BCL6b Mediates the Enhanced Magnitude of the Secondary Response of Memory CD8+ T Lymphocytes
26. Antigen-Independent Memory CD8 T Cells Do Not Develop during Chronic Viral Infection
27. Bio-active lipids protect against immune-related adverse events due to immune checkpoint blockade therapy
28. EGFR+ lung adenocarcinomas coopt alveolar macrophage metabolism and function to support EGFR signaling and growth
29. Abstract 3287: A bedside to bench study of anti-PD-1, anti-CD40, and anti-CSF1R indicates that more is not necessarily better
30. Table S1 from Impaired HLA Class I Antigen Processing and Presentation as a Mechanism of Acquired Resistance to Immune Checkpoint Inhibitors in Lung Cancer
31. Supplementary Figure Legends from Impaired HLA Class I Antigen Processing and Presentation as a Mechanism of Acquired Resistance to Immune Checkpoint Inhibitors in Lung Cancer
32. Data from Impaired HLA Class I Antigen Processing and Presentation as a Mechanism of Acquired Resistance to Immune Checkpoint Inhibitors in Lung Cancer
33. Supplementary Figures from Impaired HLA Class I Antigen Processing and Presentation as a Mechanism of Acquired Resistance to Immune Checkpoint Inhibitors in Lung Cancer
34. Supplementary Methods from Impaired HLA Class I Antigen Processing and Presentation as a Mechanism of Acquired Resistance to Immune Checkpoint Inhibitors in Lung Cancer
35. The β1-adrenergic receptor links sympathetic nerves to T cell exhaustion.
36. Tick-TOX, it’s time for T cell exhaustion
37. Trial Protocol from A Phase I Study of APX005M and Cabiralizumab with or without Nivolumab in Patients with Melanoma, Kidney Cancer, or Non–Small Cell Lung Cancer Resistant to Anti-PD-1/PD-L1
38. Supplemental Figure 1B from A Phase I Study of APX005M and Cabiralizumab with or without Nivolumab in Patients with Melanoma, Kidney Cancer, or Non–Small Cell Lung Cancer Resistant to Anti-PD-1/PD-L1
39. Supplemental Figure 2A from A Phase I Study of APX005M and Cabiralizumab with or without Nivolumab in Patients with Melanoma, Kidney Cancer, or Non–Small Cell Lung Cancer Resistant to Anti-PD-1/PD-L1
40. Supplementary Data from Drug Sensitivity and Allele Specificity of First-Line Osimertinib Resistance EGFR Mutations
41. Supplementary cfDNA Mutation Dataset from Drug Sensitivity and Allele Specificity of First-Line Osimertinib Resistance EGFR Mutations
42. Data from Drug Sensitivity and Allele Specificity of First-Line Osimertinib Resistance EGFR Mutations
43. Supplementary Figure 2 from Immune-Based Antitumor Effects of BRAF Inhibitors Rely on Signaling by CD40L and IFNγ
44. Supplementary Figure 1 from Immune-Based Antitumor Effects of BRAF Inhibitors Rely on Signaling by CD40L and IFNγ
45. Supplementary Figure 6 from Immune-Based Antitumor Effects of BRAF Inhibitors Rely on Signaling by CD40L and IFNγ
46. Supplementary Figure 7 from Immune-Based Antitumor Effects of BRAF Inhibitors Rely on Signaling by CD40L and IFNγ
47. Data from Immune-Based Antitumor Effects of BRAF Inhibitors Rely on Signaling by CD40L and IFNγ
48. Supplementary Figure 9 from Immune-Based Antitumor Effects of BRAF Inhibitors Rely on Signaling by CD40L and IFNγ
49. Supplementary Figure 8 from Immune-Based Antitumor Effects of BRAF Inhibitors Rely on Signaling by CD40L and IFNγ
50. Supplementary Figure 3 from Immune-Based Antitumor Effects of BRAF Inhibitors Rely on Signaling by CD40L and IFNγ
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.